NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis-Reference-Cited by-同舟云学术

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

Published:2019-04-10 Issue:4 Volume:71 Page:1198-1212
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Harrison Stephen A.¹²,Rossi Stephen J.³,Paredes Angelo H.⁴,Trotter James F.⁵,Bashir Mustafa R.⁶,Guy Cynthia D.⁷,Banerjee Rajarshi⁸,Jaros Mark J.⁹,Owers Sandra²,Baxter Bryan A.³,Ling Lei³,DePaoli Alex M.³

Affiliation:

1. Radcliffe Department of Medicine University of Oxford UK

2. Pinnacle Clinical Research San Antonio TX

3. NGM Biopharmaceuticals South San Francisco CA

4. San Antonio Military Medical Center San Antonio TX

5. Clinical Research and Education Texas Digestive Disease Consultants Dallas TX

6. Radiology and Medicine (Gastroenterology) Duke University Durham NC

7. Pathology Duke University Durham NC

8. Perspectum Diagnostics Oxford UK

9. Summit Analytical Denver CO

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30590

Reference32 articles.

1. Nonalcoholic Fatty Liver Disease

2. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States

3. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

4. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

5. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

Cited by 211 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. The role of FGF19 in metabolic regulation: insights from preclinical models to clinical trials;American Journal of Physiology-Endocrinology and Metabolism;2024-09-01

3. Targeting NTCP for liver disease treatment: A promising strategy;Journal of Pharmaceutical Analysis;2024-09

4. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

5. Cross‐sectional and Mendelian randomization study of fibroblast growth factor 19 reveals causal associations with metabolic diseases;Journal of Gastroenterology and Hepatology;2024-08